Cell - Citizens For Ecological Learning & Living

Cell - Citizens For Ecological Learning & Living company information, Employees & Contact Information

Updated June 2026

Quick answer

Cell - Citizens For Ecological Learning & Living is a Non-profit Organizations company and founded in 2010. It has approximately 12 employees on record. Contact data was last refreshed in June 2026. Find Cell - Citizens For Ecological Learning & Living's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Since its creation in 2010, CELL has been creating and supporting local and regional ecological and social transition projects, such as community gardens, third places, Repair Cafés, eco-social entrepreneurship and energy cooperatives.
Looking for a particular Cell - Citizens For Ecological Learning & Living employee's phone or email?

Cell - Citizens For Ecological Learning & Living Questions

News

Diversity of BRAF mutations in non-small cell lung cancer and implications on treatment - Nature

Diversity of BRAF mutations in non-small cell lung cancer and implications on treatment Nature

Non-Small Cell Lung Cancer (NSCLC): Background, Pathophysiology, Etiology - Medscape eMedicine

Non-Small Cell Lung Cancer (NSCLC): Background, Pathophysiology, Etiology Medscape eMedicine

NICE recommends first immunotherapy for limited-stage small cell lung cancer - The Pharmaceutical Journal

NICE recommends first immunotherapy for limited-stage small cell lung cancer The Pharmaceutical Journal

Comparative Analysis of Cell Damage Induced by Lu-177 and Tb-161: Insights into Auger Electrons and Therapeutic Efficiency - Journal of Nuclear Medicine

Comparative Analysis of Cell Damage Induced by Lu-177 and Tb-161: Insights into Auger Electrons and Therapeutic Efficiency Journal of Nuclear Medicine

Updated overall survival data and predictive biomarkers of autologous NK cells plus Sintilimab as second-line treatment for advanced non-small cell lung cancer - Frontiers

Updated overall survival data and predictive biomarkers of autologous NK cells plus Sintilimab as second-line treatment for advanced non-small cell lung cancer Frontiers

ALK and Lung Cancer - American Lung Association

ALK and Lung Cancer American Lung Association

Neoadjuvant Aumolertinib for unresectable stage III EGFR -mutant non-small cell lung cancer: a single-arm phase II trial - Nature

Neoadjuvant Aumolertinib for unresectable stage III EGFR -mutant non-small cell lung cancer: a single-arm phase II trial Nature

Real-world outcomes of immune checkpoint inhibitors as second-line therapy for extensive-stage small-cell lung cancer: a multicenter retrospective analysis - Frontiers

Real-world outcomes of immune checkpoint inhibitors as second-line therapy for extensive-stage small-cell lung cancer: a multicenter retrospective analysis Frontiers

LU joins Agenda 2030 with new cell for SDGs - Times of India

LU joins Agenda 2030 with new cell for SDGs Times of India

Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial - The Lancet

Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial The Lancet

Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer - The New England Journal of Medicine

Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer The New England Journal of Medicine

Pharmacologic modulation of RNA splicing enhances anti-tumor immunity - ScienceDirect.com

Pharmacologic modulation of RNA splicing enhances anti-tumor immunity ScienceDirect.com

Trajectories of Perioperative Serum CEA and Non-Small Cell Lung Cancer Prognosis: A Retrospective Longitudinal Cohort Study - Frontiers

Trajectories of Perioperative Serum CEA and Non-Small Cell Lung Cancer Prognosis: A Retrospective Longitudinal Cohort Study Frontiers

Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial - Nature

Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial Nature

68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study - Journal of Nuclear Medicine

68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study Journal of Nuclear Medicine

Integration of clinical, pathological, radiological, and transcriptomic data improves prediction for first-line immunotherapy outcome in metastatic non-small cell lung cancer - Nature

Integration of clinical, pathological, radiological, and transcriptomic data improves prediction for first-line immunotherapy outcome in metastatic non-small cell lung cancer Nature

Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer - Frontiers

Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer Frontiers

Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials - Nature

Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials Nature

A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer - Nature

A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer Nature

-mutated nonsmall-cell lung cancer: a phase 2b trial - Nature

-mutated nonsmall-cell lung cancer: a phase 2b trial Nature

Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer - Nature

Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer Nature

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer - The New England Journal of Medicine

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer The New England Journal of Medicine

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer - The New England Journal of Medicine

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer The New England Journal of Medicine

Unraveling the Connection: Extracellular Vesicles and Non-Small Cell Lung Cancer - Dove Medical Press

Unraveling the Connection: Extracellular Vesicles and Non-Small Cell Lung Cancer Dove Medical Press

Long non-coding RNAs in non-small cell lung cancer: implications for EGFR-TKI resistance - Frontiers

Long non-coding RNAs in non-small cell lung cancer: implications for EGFR-TKI resistance Frontiers

MEK inhibitors for the treatment of non-small cell lung cancer - Journal of Hematology & Oncology

MEK inhibitors for the treatment of non-small cell lung cancer Journal of Hematology & Oncology

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer - The New England Journal of Medicine

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer The New England Journal of Medicine

Drug repositioning in non-small cell lung cancer (NSCLC) using gene co-expression and drug–gene interaction networks analysis - Nature

Drug repositioning in non-small cell lung cancer (NSCLC) using gene co-expression and drug–gene interaction networks analysis Nature

Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer - Nature

Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer Nature

Dynamic surveillance of lymphocyte subsets in patients with non-small cell lung cancer during chemotherapy or combination immunotherapy for early prediction of efficacy - Frontiers

Dynamic surveillance of lymphocyte subsets in patients with non-small cell lung cancer during chemotherapy or combination immunotherapy for early prediction of efficacy Frontiers

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer - The New England Journal of Medicine

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer The New England Journal of Medicine

Advances in CAR-NK cell therapy for lung cancer: is it a better choice in the future? - Frontiers

Advances in CAR-NK cell therapy for lung cancer: is it a better choice in the future? Frontiers

Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer - The New England Journal of Medicine

Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer The New England Journal of Medicine

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer - The New England Journal of Medicine

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer The New England Journal of Medicine

Single-Cell Analysis of Human Retina Identifies Evolutionarily Conserved and Species-Specific Mechanisms Controlling Development - ScienceDirect.com

Single-Cell Analysis of Human Retina Identifies Evolutionarily Conserved and Species-Specific Mechanisms Controlling Development ScienceDirect.com

A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma - Nature

A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma Nature

Identification of multiple organ metastasis-associated hub mRNA/miRNA signatures in non-small cell lung cancer - Nature

Identification of multiple organ metastasis-associated hub mRNA/miRNA signatures in non-small cell lung cancer Nature

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR - The New England Journal of Medicine

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR The New England Journal of Medicine

KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors - Nature

KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors Nature

Lung Cancer: Types, Stages, Symptoms, Diagnosis & Treatment - Cleveland Clinic

Lung Cancer: Types, Stages, Symptoms, Diagnosis & Treatment Cleveland Clinic

Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes - Nature

Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes Nature

What Is Your Outlook When SCLC Spreads to the Brain? - Healthline

What Is Your Outlook When SCLC Spreads to the Brain? Healthline

Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients - Nature

Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients Nature

T Cell-Released Extracellular Vesicles Potentiate the Efficacy of the HBsAg Vaccine by Enhancing B Cell Responses - Wiley Online Library

T Cell-Released Extracellular Vesicles Potentiate the Efficacy of the HBsAg Vaccine by Enhancing B Cell Responses Wiley Online Library

New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe - The Lancet

New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe The Lancet

GATA6 Exerts Potent Lung Cancer Suppressive Function by Inducing Cell Senescence - Frontiers

GATA6 Exerts Potent Lung Cancer Suppressive Function by Inducing Cell Senescence Frontiers

MiR-27a-3p Promotes Non-Small Cell Lung Cancer Through SLC7A11-Mediated-Ferroptosis - Frontiers

MiR-27a-3p Promotes Non-Small Cell Lung Cancer Through SLC7A11-Mediated-Ferroptosis Frontiers

Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity - Nature

Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity Nature

Metastatic lung cancer life expectancy: Survival rates and more - Medical News Today

Metastatic lung cancer life expectancy: Survival rates and more Medical News Today

Stemness and inducing differentiation of small cell lung cancer NCI-H446 cells - Nature

Stemness and inducing differentiation of small cell lung cancer NCI-H446 cells Nature

Prognostic and predictive factors for lung cancer - ERS - European Respiratory Society

Prognostic and predictive factors for lung cancer ERS - European Respiratory Society

Risk Factors and Treatment of Squamous Cell Carcinoma in the Lungs - Verywell Health

Risk Factors and Treatment of Squamous Cell Carcinoma in the Lungs Verywell Health

Expansion of the Hadley cell under global warming - Lu - 2007 - Geophysical Research Letters - AGU Publications

Expansion of the Hadley cell under global warming - Lu - 2007 - Geophysical Research Letters AGU Publications

Top Cell - Citizens For Ecological Learning & Living Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant